Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

interchemie werken de adelaar eesti as - borsyra; kalciumglukonat (monohydrat); magnesiumkloridhexahydrat - infusionsvätska, lösning - 380/60/50 mg/ml - magnesiumkloridhexahydrat 60 mg aktiv substans; kalciumglukonat (monohydrat) 380 mg aktiv substans; borsyra 50 mg aktiv substans - får, nöt, svin

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

bela-pharm gmbh & co. kg - borsyra; kalciumglukonat (monohydrat); magnesiumkloridhexahydrat - infusionsvätska, lösning - 240/60/60 mg/ml - borsyra 60 mg aktiv substans; magnesiumkloridhexahydrat 60 mg aktiv substans; kalciumglukonat (monohydrat) 240 mg aktiv substans - får, get, häst, nöt, svin

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - minskning av förhöjt intraokulärt tryck hos vuxna patienter med okulär hypertension eller öppenvinkelglaukom (se avsnitt 5. sänkning av förhöjt intraokulärt tryck på pediatriska patienter i åldern 3 år till < 18 år med okulär hypertension eller glaukom pediatriska.

Finlandja - Svediż - Ecolab

ecolab deutschland gmbh -

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

evolan pharma ab - kalciumkarbonat; magnesiumhydroxid - tuggtablett - 180 mg / 43,7 mg - kalciumkarbonat 450,51 mg aktiv substans; magnesiumhydroxid 104,85 mg aktiv substans; sorbitol hjälpämne

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

accord healthcare s.l.u. - ibandronsyra - wounds and injuries; breast diseases; neoplastic processes; calcium metabolism disorders; water-electrolyte imbalance - läkemedel för behandling av bensjukdomar - ibandronic acid är indicerat hos vuxna forprevention av skelett händelser (patologiska frakturer, ben komplikationer som kräver strålning eller operation) hos patienter med bröstcancer och benmetastaser. behandling av tumör inducerad hypercalcaemia med eller utan metastaser. behandling av osteoporos hos postmenopausala kvinnor med ökad risk för fraktur (se avsnitt 5. en minskning i risken för vertebrala frakturer har visats effekt på brott på lårbenshalsen har inte fastställts.

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

viatris ab - kalciumkarbonat; magnesiumhydroxid - tuggtablett - mannitol hjälpämne; xylitol hjälpämne; magnesiumhydroxid 104 mg aktiv substans; kalciumkarbonat 449 mg aktiv substans; sorbitol hjälpämne - kalcium- och magnesiumsalter